Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 20Thoracic 2Sarcoma 2Gynecologic 2Gastrointestinal 2Dermatologic 2NET 1Lymphoid 1Head & Neck 1Endocrine 1

Conditions

Neuroendocrine Tumors 73Carcinoma, Neuroendocrine 27Pheochromocytoma 24Thyroid Cancer, Papillary 23Thyroid Neoplasms 21Pituitary Neoplasms 21Adrenocortical Carcinoma 19Paraganglioma 16Multiple Endocrine Neoplasia Type 1 14Neuroblastoma 12Sarcoma 11Adenoma, Islet Cell 11Small Cell Lung Carcinoma 10Neoplasms 10Melanoma 10Lung Neoplasms 9Carcinoid Tumor 9Adrenal Gland Neoplasms 9Adenocarcinoma, Follicular 9Pancreatic Neoplasms 8Gastro-enteropancreatic neuroendocrine tumor 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Medullary 8Thyroid Carcinoma, Anaplastic 7Neoplasm Metastasis 7Mesothelioma 7Cushing Syndrome 7Cholangiocarcinoma 7Central Nervous System Neoplasms 7Breast Neoplasms 7

Interventions

cabozantinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clear-cell metastatic renal cell carcinoma × Endocrine × 90 days × Clear all
NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2 Recruiting
111 enrolled
EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡